<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627757</url>
  </required_header>
  <id_info>
    <org_study_id>HC-2007-0069</org_study_id>
    <secondary_id>2602-706</secondary_id>
    <nct_id>NCT00627757</nct_id>
  </id_info>
  <brief_title>Antipsychotic Medicine and Metabolic Syndrome</brief_title>
  <acronym>AMMS1</acronym>
  <official_title>Changes in Enteroendocrine and Neuroendocrine Axes in Patients With Weight Gain After Treatment With Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether antipsychotic treatment is influence
      psychiatric patients due to endocrine and metabolic status and a quality of life.

      The investigators expect, that 30-50% of patients will show pharmacon - gene induced weight
      gain (&gt; 7% of initial bodyweight) while the rest of patients will maintain unaltered
      bodyweight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to investigate status of neuro-and enteroendocrine axes with
      focus on beta - cell function in relation to insulin resistance, lipid profile abnormalities
      and inflammations adipokins in patients during treatment with antipsychotics (AP) in relation
      to weight gain.

      The second aim is to evaluate the connection between weight gain and patients´ own perception
      of their quality of life and health.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Food challenge test</arm_group_label>
    <description>Patients
51 patients included</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>Controls 93 healthy controls are included</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50 patients and 100 control persons. Patients should be treated with minimum one
        antipsychotic drug and hospitalized or treated as out-patients at Glostrup, Ballerup or
        Gentofte hospitals.

        Controls will be chosen from the database at Institute of Health and Prevention, Glostrup.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gender : male

          -  age: 18-45

          -  treatment with minimum one Antipsychotic drug (AP)

          -  ethnicity: caucasians

          -  consent given to take part in the project

        Exclusion Criteria:

        One criteria is sufficient to exclude patients from the study:

          -  compliance problems

          -  unable to read, write and talk Danish

          -  patients with major lung-,heart-, lever- and kidney problems

          -  patients with diagnose and treatment for Diabetes 1 and 2

          -  patients taking cholesterol-reducing, weight-reducing and antihypertensive medication

          -  patients with abuse of alcohol or drugs

          -  patients who are under duress §

          -  patients who have been mentally ill for more than 15 years

          -  patients with diagnosis/treatment for NIDDM/IDDM
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Lublin, MD DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup University Hospital, Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Lublin, MD DMSc</last_name>
    <phone>045-43233540</phone>
    <email>henlub01@glo.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Psychiatric University Center Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Lublin, MD DMSc</last_name>
      <phone>045-43233540</phone>
      <email>henlub01@glo.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Henrik Lublin, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric University Center Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Lublin, MD DMSc</last_name>
      <phone>045-43233540</phone>
      <email>henlub01@glo.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Henrik Lublin, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2008</study_first_posted>
  <last_update_submitted>July 29, 2010</last_update_submitted>
  <last_update_submitted_qc>July 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Henrik Lublin MD DMSc, Chairman and Associate Pofessor of Psychiatry</name_title>
    <organization>Psychiatric University Center Glostrup Copenhagen University Hospitals</organization>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>weight gain</keyword>
  <keyword>antipsychotic drugs</keyword>
  <keyword>Metabolic syndrome and treatment with antipsychotic drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

